McMMAF

McMMAF (Maleimidocaproyl monomethylauristatin F) is an active molecule linker for ADC, made by coupling the powerful microtubule inhibitor Monomethyl auristatin F (MMAF) (HY-15579) with the protecting group maleimidocaproyl. McMMAF can be conjugated with anti-BCMA antibodies to form J6M0-mcMMAF, promoting apoptosis and inhibiting tumor growth[1][2][3][4].

Product Specifications

CAS Number

[863971-19-1]

Product Name Alternative

Maleimidocaproyl monomethylauristatin F

UNSPSC

12352203

Hazard Statement

H300, H310, H330

Target

Apoptosis; Drug-Linker Conjugates for ADC

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related; Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/McMMAF.html

Purity

99.97

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C([C@H](C)[C@H]([C@]1([H])CCCN1C(C[C@@H](OC)[C@@]([H])(N(C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C(CCCCCN2C(C=CC2=O)=O)=O)=O)=O)C)[C@@H](C)CC)=O)OC)N[C@H](C(O)=O)CC3=CC=CC=C3

Molecular Formula

C49H76N6O11

Molecular Weight

925.16

Precautions

H300, H310, H330

References & Citations

[1]Polson AG, et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res. 2009 Mar 15;69 (6) :2358-2364.|[2]Jianmin Fang, et al. Anti-her2 antibody and conjugate thereof. US 20160304621 A1.|[3]Yu-Tzu Tai, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014 May 15;123 (20) :3128-38. |[4]Katja Weisel, et al. Dreamm-3: A Phase 3, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin (GSK2857916) Monotherapy Compared with Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) . Blood. 13 November 2019, Page 1900.